← Leaderboards
Jules Leonard Dienstag
Massachusetts General Hospital
$2,593,891
Attributed
$2,593,891
Total exposure
9
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $86.5K · FY2005–08$100K$75K$50K$25K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$2,593,891 · 9
By mechanism
M01$2,382,823 · 8
N01$211,068 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Raymond T Chung$38,306,004
- Martin L Yarmush$31,545,312
- Zdravka O. Medarova$10,579,501
- Georg Michael Lauer$24,583,765
- Bruce D Walker$50,324,331
Others in their field
Top investigators on “Hepatitis C”
- Constance Ann Benson · University Of California, San Diego$171,085,251
- Sharon A Nachman · Johns Hopkins University$116,441,543
- Peter B. Gilbert · Fred Hutchinson Cancer Center$94,107,997
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Richard Douglas Moore · Johns Hopkins University$59,121,971
- Charles R Rinaldo · University Of Pittsburgh At Pittsburgh$46,122,050
Research focus
Hepatitis CHuman Therapy EvaluationHuman SubjectClinical ResearchInterferon AlphaLiver Disorder ChemotherapyDrug Screening /EvaluationRibavirinPolyethylene GlycolsCombination ChemotherapyHepatitis C VirusInterferonsDosageChronic Disease /DisorderMicroorganism Disease ChemotherapyDrug Administration Rate /DurationDosage FormsVirus LoadImmunotherapyClinical TrialsClinical Trial Phase IAntiviral AgentsBiopsyCirrhosis
Grant awards (22)
CLINICAL TRIAL: THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS$4,209
M01 · FY2008 · RR · contact PI
THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL$29,576
M01 · FY2007 · RR · contact PI
THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL$61,195
M01 · FY2006 · RR · contact PI
THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL$86,543
M01 · FY2005 · RR
THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL$163,709
M01 · FY2004 · RR
PEG-INF VS INTRON A FOR PATIENTS WITH CHRONIC HEPATITIS C NAIVE TO INTERFERON$200,768
M01 · FY2002 · RR
PEG Interferon alpha + Ribavirin for Chronic Hepatitis C$200,768
M01 · FY2002 · RR
PEG Interferon alpha + Ribavirin for Chronic Hepatitis C$200,768
M01 · FY2002 · RR
PEG-INF VS INTRON A FOR PATIENTS WITH CHRONIC HEPATITIS C NAIVE TO INTERFERON$200,768
M01 · FY2002 · RR
PEG-INF VS INTRON A FOR PATIENTS WITH CHRONIC HEPATITIS C NAIVE TO INTERFERON$200,768
M01 · FY2001 · RR
PEG Interferon alpha + Ribavirin for Chronic Hepatitis C$200,768
M01 · FY2001 · RR
PEG Interferon alpha + Ribavirin for Chronic Hepatitis C$0
M01 · FY2001 · RR
PEG-INF VS INTRON A FOR PATIENTS WITH CHRONIC HEPATITIS C NAIVE TO INTERFERON$0
M01 · FY2001 · RR
INTRON A VS INTRON A PLUS RIBAVIRIN AT 2 DOSES TO TREAT CHRONIC HEPATITIS C$415,629
M01 · FY2000 · RR
INTRON A MONOTHERAPY VS INTRON A+ RIBAVIRIN FOR TREATMENT OF CHRONIC HEPATITIS C$415,629
M01 · FY2000 · RR
HEPATITIS C CLINICAL TRIAL-CLINICAL CENTERS$211,068
N01 · FY2000 · DK
INTRON A MONOTHERAPY VS INTRON A+ RIBAVIRIN FOR TREATMENT OF CHRONIC HEPATITIS C$575
M01 · FY2000 · RR
PEG-INF VS INTRON A FOR PATIENTS WITH CHRONIC HEPATITIS C NAIVE TO INTERFERON$575
M01 · FY2000 · RR
INTRON A VS INTRON A PLUS RIBAVIRIN AT 2 DOSES TO TREAT CHRONIC HEPATITIS C$575
M01 · FY2000 · RR
PEG Interferon alpha + Ribavirin for Chronic Hepatitis C$0
M01 · FY2000 · RR
PEG Interferon alpha + Ribavirin for Chronic Hepatitis C$0
M01 · FY2000 · RR
PEG-INF VS INTRON A FOR PATIENTS WITH CHRONIC HEPATITIS C NAIVE TO INTERFERON$0
M01 · FY2000 · RR